Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mindset Pharma Inc (OP: MSSTF )

0.1788 +0.0162 (+9.96%)
Streaming Delayed Price Updated: 3:34 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Mindset Pharma Inc

< Previous 1 2 3 Next >
Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More
Psychedelics Reform Update: 22 States Where Proposals Are Being Discussed & Local Moves Considered 
Via Benzinga
Two Major Psychedelics Companies Take Novel Chemical Entity Patent Battle To Federal Court
Clinical-stage biopharma company Reunion Neuroscience Inc. (NASDAQ: REUN) filed a lawsuit against drug discovery business Mindset Pharma Inc. (OTCQB: MSSTF) in the District Court of New Jersey. 
Via Benzinga
Psyched: Next-Gen Compounds For Depression, Congress, Rescheduling, Benzinga Psychedelics Conference & More
Major Depressive Disorder: Small Pharma’s Phase 2 DMT Trial, BetterLife’s Preclinical LSD Trial 
Via Benzinga
Australia Receives First Batch Of Clinical-Grade Psilocybin From Mindset Pharma And PharmAla
The exclusive sales partnership between psychedelics biotechs Mindset Pharma (OTCQB: MSSTF) and PharmAla Holdings resulted in the first sale of Mindset’s GMP-compliant psilocybin in Australia. 
Via Benzinga
Silo Pharma, Mindset Pharma, Terran Biosciences Receive Psychedelic Treatments Patents, IP Portfolios Expanded
Silo Pharma Sees Growth In IP With New US Patent For Novel Ketamine Method On Stress-Induced Affective Disorders 
Via Benzinga
Psyched: States With Psychedelics Legalization Bills, Next-Gen Molecule For Addiction Treatment And More
Legalizing Psychedelics From New York To Washington And Five In Between: Which State Will Go First? 
Via Benzinga
Search Is On For Psychedelic Patents & FDA Designations, 3 Companies Share News
Drug discovery company Mindset Pharma (OTCQB: MSSTF) has been greenlighted by the US Patent and Trademark Office (USPTO) on its application “Psilocin Derivatives As Serotonergic Psychedelic Agents for... 
Via Benzinga
Psyched: Musk's Empathy Tweets, Psychedelics In Congress, Oregon's Opt-Outs, MAPS' MDMA Trial And More
Elon Musk Joins Twitter Conversation Around Psychedelics: A Debate On Empathy 
Via Benzinga
These Two Psychedelics Companies Team Up In An Exclusive Sales Deal, Here Are The Details
Next-gen psychedelics producers Mindset Pharma Inc. (OTCQB: MSSTF) and PharmAla Biotech Holdings Inc. 
Via Benzinga
EXCLUSIVE: Insider's Peek At Mammoth Of Psychedelics VCs, Palo Santo, Market Subverticals & Informal Guidance
(Part four of a four-part series) See previous stories in this series:  
Via Benzinga
European Psychedelics Research Group Nabs $2M In Seed Funding As Clinical Research Picks Up Speed
UK psychedelics clinical research organization Clerkenwell Health raised $2.047.710 (£2.1 million) in seed funding, bringing the total to date up to $2.437.750 (£2.5 million), all of which will be used... 
Via Benzinga
Psyched: CA's Psychedelic-Assisted Treatments, Ketamine Therapy, Near-Death Experience And More
Alberta Becomes The First Canadian Province To Regulate Psychedelics-Assisted Therapy 
Via Benzinga
Next-Generation Psychedelics Shows Promise With Upcoming Clinical Trials
Biopharma R&D company Mindset Pharma Inc. 
Via Benzinga
Cybin Acquires Exclusive License To Mindset Pharma's Tryptamine Compounds Family
Through its wholly-owned subsidiary, Cybin IRL Limited, Canadian-based psychedelics biotech Cybin Inc. (NYSE AMERICAN: CYBN) signed an agreement with next-gen psychedelics producer Mindset Pharma Inc. 
Via Benzinga
Mindset Pharma Meets With UK Regulator: Is A Phase 1 Trial Getting Close?
Biotech drug discovery firm Mindset Pharma Inc. 
Via Benzinga
Psychedelics Companies Explore & Protect Their Findings, This Firm Is Doing That In 16 Countries
Psychedelics R&D company Mindset Pharma (OTCQB: MSSTF) has filed no less than 16 national applications, including countries within the main South East Asian markets, for one of its key families of... 
Via Benzinga
Psychedelic Stock Gainers And Losers From September 7, 2022
GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 5.66% at $1.12 
Via Benzinga
Most, But Not All, Psychedelics Companies Have Sufficient Liquidity
The Chart represents the liquidity positions of the 21 Psychedelic sector companies in the Viridian Value Tracker database. 
Via Benzinga
Small Pharma, Revive Therapeutics Among Top Psychedelic Movers Of Today
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 6.41% at $0.29 
Via Benzinga
This Company Just Created 3 Brand New Psychedelics—Without The Hallucinogenic Side Effects
Mindset Pharma Inc. (OTCQB: MSSTF), a company producing psychedelic and non-psychedelic drugs for mental health conditions has recently identified three additional families of highly novel,... 
Via Benzinga
Intranasal Psychedelics Platform Is Here, Check Out Mindset's New Development
In the process of creating optimized next-generation psychedelic medicines for neurological and psychiatric disorders, drug discovery and development company Mindset Pharma Inc. 
Via Benzinga
Mindset Partners With Canadian Psychiatric Research Hospital For Preclinical Study Of Psilocybin-Derived MSP-1014
Mindset Pharma Inc. 
Via Benzinga
Psyched: Elon Musk Tweets About Psychedelics, Numinus Acquires Novamind, Colorado Gov. Signs MDMA Legalization Bill
Want to get the latest psychedelics industry news in your inbox every week? Subscribe to our Newsletter to become a Psychedelics Insider. 
Via Benzinga
Mindset Approved For Patent Application Involving Psilocin Derivatives For Central Nervous System Disorders
Mindset Pharma Inc. 
Via Benzinga
Psychedelic Medicine: The New Frontier In Healthcare, The Big Opportunity In Biopharma
The story around psychedelic medicine continues to get bigger. 
Via Talk Markets
Psychedelic Drug Patenting: Still Only Scratching The Surface
Psychedelic drug R&D remains in its infancy, with dozens of psychedelics and several 
Via Talk Markets
Revive Therapeutics, Cybin Among Top Psychedelic Movers Of Today
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 14.54% at $0.16 
Via Benzinga
Revive Therapeutics, Field Trip Health Among Top Psychedelic Movers Of Today
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 14.48% at $0.14 
Via Benzinga
Intelgenx Technologies, Field Trip Health Among Top Psychedelic Movers Of Today
GAINERS: GH Research (NASDAQ:GHRS) shares closed up 4.78% at $19.73 LOSERS: 
Via Benzinga
Psychedelic Stock Gainers And Losers From April 5, 2022
GAINERS: Field Trip Health (NASDAQ:FTRP) shares closed up 1.60% at $1.27 LOSERS: 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.